Yimiao Shenzhou Honored as BIOCHINA 2025 Top 100 Innovative Breakthrough Enterprise for Third Consecutive Year
Imunopharm
Developer of Gene and Cell Therapy Technologies
On March 13, BIOCHINA 2025 (10th) EMBIO Biotechnology Exhibition grandly opened at the Suzhou International Expo Center, with the release of the BIOCHINA Awards list. Beijing Yimiaoshenzhou Medical Techology Co., Ltd., recognized for its continuous innovation and breakthroughs in the gene and cell drug field over the past year, was selected by expert judges to be on the BIOCHINA Awards list for the third consecutive year, earning the title of "Top 100 Innovative Breakthrough Enterprises."Selected as one of the top 100 innovative breakthrough companies for three consecutive years,Fully reflects the industry's high praise and widespread consensus on the company's innovative leadership in the field of CAR-T innovative drug research and development.Dr. He Ting, CEO of the company, was invited to attend the conference and received the trophy on site.
Dr. He Ting, CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., receiving the award on site (3rd from the left)
BIOCHINA has long focused on the innovation and transformation of the biotechnology industry, with a foundation in the innovative drug track, promoting the dissemination of cutting-edge developments and sharing experiences in scientific research achievements, clinical needs, industrial transformation, and business development across the entire industry chain; The BIOCHINA Awards selection, through expert reviews and comprehensive evaluations of multi-dimensional real data, aims to discover innovative forces in the biopharmaceutical industry and collaborate with all parties to promote industrial development.
In the past year, Yimiao Shenzhou has made progress in the gene cell drug product pipeline andNew Technology PlatformContinuous innovation in R&D has led to several milestone breakthroughs. The hematological oncology product IM19 targets relapsed or refractory diffuse large B-cell lymphoma indications.Internationally Leading Safety and Efficacy DataCompleted clinical trials, and the New Drug Application (NDA) has been officially accepted by the National Medical Products Administration; IM96 and IM83, two CAR-T products for solid tumors, and ZM001 for autoimmune diseases have entered Phase I clinical stage, successfully enrolling multiple patients. Significant progress has been made in the development of next-generation gene and cell therapy technology platforms, including rapid CAR-T, universal CAR-T, and gene editing, positioning them as leading in China. Additionally, the company announced in January 2025 the completion ofInvested by multiple well-known investment institutionsSeries E Financing Injects Strong Momentum into Accelerating the Development of New Gene and Cell Drug Processes and New Product Clinical Trials
Looking ahead, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. will accelerate the clinical transformation and application of new drugs in the vast blue ocean of gene and cell therapy, writing a brilliant chapter for China's innovative pharmaceutical companies.Foster new quality productive forces in the biopharmaceutical industry and contribute core momentum to the construction of Healthy China!
// About Yimiao Shenzhou //
Founded in 2015 and headquartered in Beijing, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. is a leading innovative pharmaceutical company with the mission of "making cancer no longer an incurable disease." The company focuses on applying proprietary gene-cell drug technology to treat major diseases (such as cancer and autoimmune diseases). To date, the company has completed 10 rounds of strategic financing and owns a one-stop, self-developed gene-cell drug R&D and industrialization platform. It has mastered several core technologies, won the top prize in the finals of China's Disruptive Technology Innovation Competition, obtained clinical trial approval for seven Class 1 new drugs, and received Beijing’s first-ever Drug Manufacturing License for gene-cell therapy. Its R&D pipeline covers hematological cancers such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, and melanoma. Among these, its first blood cancer CAR-T product, IM19, targeting relapsed or refractory diffuse large B-cell lymphoma, has submitted a New Drug Application (NDA) which has been accepted.
The company has undertaken more than 10 national and provincial scientific research projects, including the Special Project of the National Key R&D Program by the Ministry of Science and Technology, the Major Innovation Project for Science and Technology under the National Health Commission’s "2030" plan, the "Challenge Grant" technical project on cell therapy by the National Innovation Center, and the Beijing Municipal Science and Technology Major Special Project. It has obtained important qualifications such as a National High-tech Enterprise, a Beijing-based specialized, refined, distinctive, and innovative enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Haidian District Haiying Talent of Beijing, Xingguomen Leading Talent of Daxing District in Beijing, the Gold Award (First Place) at Tsinghua University President's Cup Innovation Challenge, MIT's 35 Innovators Under 35, and Fortune Magazine's 40 Under 40 Business Elites.
